AgriFood specialists S2G Ventures and Lewis and Clark Ventures also participated in the round alongside Macro Capital Investments and the majority of GreenLight’s existing investors, including Kodiak Venture Partners, MLSCF, Syngenta Ventures and others.
This round brings Greenlight’s total disclosed fundraising to $46 million, though the value of the company’s Series C round in 2015 was undisclosed.
Greenlight’s technology targets pests’ RNA, the material that DNA employs to communicate what proteins to build, so that essential proteins are not manufactured, causing the death of certain insects and other pests.
Because the pesticide, which is made of double-stranded RNAs (dsRNA), is so targeted, it only affects the intended organisms and does not affect the plant or those that consume the plants.
According to the company’s website, large-scale production of RNA has traditionally been prohibitively expensive.
GreenLight plans to use the new funds to accelerate the development and field testing of a number of dsRNA molecules targeting insect and viral pests in high-value crops.